



Live Web Streaming Details – Novogen Capital Raising Investor Presentation and Q & A Session

Alongside the physical presentations through Sydney and Melbourne, Novogen will be hosting a live webinar on the 29th October, 2014 to allow for existing investors, new investors, and those considering the company for the first time to become acquainted with the management, and the cancer-fighting project at hand.

Format: Investor Presentation by Novogen CEO, Dr Graham Kelly followed by a Q & A session with Novogen Senior Executives.

Date: 29th October, 2014

Time: 12pm AEDT (NSW, VIC, TAS, ACT)

Registration Details: <https://www.media-server.com/m/go/Novogen-20141029>

OR Scan the QR code below to view on iPad/iPhone/Android Smart Devices.



Please also refer back to the Novogen website for further information on the current capital raising www.novogen.com

About Novogen Limited

Novogen is a public, Australian drug-development company whose shares trade on both the Australian Securities Exchange ('NRT') and NASDAQ ('NVGN'). The Novogen Group

includes a New Haven, Connecticut-based joint venture company, CanTx Inc., with Yale University.

Novogen has two main drug technology platforms: super-benzopyrans (SBPs) and anti-tropomyosins (ATMs). SBP compounds have been created to kill the full range of cells within a tumor, but particularly the cancer stem cells. The ATM compounds target the microfilament component of the cancer cell and when used in conjunction with standard anti-microtubular drugs, result in comprehensive and fatal destruction of the cancer cell's cytoskeleton. Ovarian cancer, colorectal cancer, malignant ascites, prostate cancer, neural cancers (glioblastoma, neuroblastoma in children) and melanoma are the key clinical indications being pursued, with the ultimate objective of employing both technologies as a unified approach to first-line therapy.

Further information is available on our website www.novogen.com


For more information please contact:

**Novogen Enquiries**

Dr Graham Kelly
CEO Novogen Group
Graham.Kelly@novogen.com
+(61 2) 9472 4100

Advisor to the Offer

Matt Christensen
Hill Capital
matthewc@hillcapital.com.au
+(61 2) 9416 5399

**Media Enquiries**

Ian Westbrook
Westbrook Communications
ian@westbrookfin.com.au
+(61 2) 9231 0922

NOVOGEN